195 related articles for article (PubMed ID: 29547881)
21. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment.
Peters PJ; Thigpen MC; Parise ME; Newman RD
Drug Saf; 2007; 30(6):481-501. PubMed ID: 17536875
[TBL] [Abstract][Full Text] [Related]
22. Piperaquine Exposure Is Altered by Pregnancy, HIV, and Nutritional Status in Ugandan Women.
Hughes E; Imperial M; Wallender E; Kajubi R; Huang L; Jagannathan P; Zhang N; Kakuru A; Natureeba P; Mwima MW; Muhindo M; Mwebaza N; Clark TD; Opira B; Nakalembe M; Havlir D; Kamya M; Rosenthal PJ; Dorsey G; Aweeka F; Savic RM
Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 33020153
[TBL] [Abstract][Full Text] [Related]
23. User and Provider Acceptability of Intermittent Screening and Treatment and Intermittent Preventive Treatment with Dihydroartemisinin-Piperaquine to Prevent Malaria in Pregnancy in Western Kenya.
Hill J; Hoyt J; Achieng F; Ouma P; L'lanziva A; Kariuki S; Desai M; Webster J
PLoS One; 2016; 11(3):e0150259. PubMed ID: 26986471
[TBL] [Abstract][Full Text] [Related]
24. Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women.
Hamer DH; Mwanakasale V; Macleod WB; Chalwe V; Mukwamataba D; Champo D; Mwananyanda L; Chilengi R; Mubikayi L; Mulele CK; Mulenga M; Thea DM; Gill CJ
J Infect Dis; 2007 Dec; 196(11):1585-94. PubMed ID: 18008241
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali.
Dama S; Niangaly H; Djimde M; Sagara I; Guindo CO; Zeguime A; Dara A; Djimde AA; Doumbo OK
Malar J; 2018 Oct; 17(1):347. PubMed ID: 30290808
[TBL] [Abstract][Full Text] [Related]
26. Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: a randomized controlled trial.
Kakuru A; Jagannathan P; Kajubi R; Ochieng T; Ochokoru H; Nakalembe M; Clark TD; Ruel T; Staedke SG; Chandramohan D; Havlir DV; Kamya MR; Dorsey G
BMC Med; 2020 Aug; 18(1):207. PubMed ID: 32772921
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquine.
Zongo I; Somé FA; Somda SA; Parikh S; Rouamba N; Rosenthal PJ; Tarning J; Lindegardh N; Nosten F; Ouédraogo JB
PLoS One; 2014; 9(8):e103200. PubMed ID: 25133389
[TBL] [Abstract][Full Text] [Related]
28. Infant sex modifies associations between placental malaria and risk of malaria in infancy.
Kakuru A; Roh ME; Kajubi R; Ochieng T; Ategeka J; Ochokoru H; Nakalembe M; Clark TD; Ruel T; Staedke SG; Chandramohan D; Havlir DV; Kamya MR; Dorsey G; Jagannathan P
Malar J; 2020 Dec; 19(1):449. PubMed ID: 33272281
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women: protocol of a multicentre, two-arm, randomised, placebo-controlled, superiority clinical trial (MAMAH project).
González R; Nhampossa T; Mombo-Ngoma G; Mischlinger J; Esen M; Tchouatieu AM; Pons-Duran C; Dimessa LB; Lell B; Lagler H; Garcia-Otero L; Zoleko Manego R; El Gaaloul M; Sanz S; Piqueras M; Sevene E; Ramharter M; Saute F; Menendez C
BMJ Open; 2021 Nov; 11(11):e053197. PubMed ID: 34815285
[TBL] [Abstract][Full Text] [Related]
30. Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy.
Chotsiri P; Gutman JR; Ahmed R; Poespoprodjo JR; Syafruddin D; Khairallah C; Asih PBS; L'lanziva A; Otieno K; Kariuki S; Ouma P; Were V; Katana A; Price RN; Desai M; Ter Kuile FO; Tarning J
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33361303
[TBL] [Abstract][Full Text] [Related]
31. Decrease of microscopic Plasmodium falciparum infection prevalence during pregnancy following IPTp-SP implementation in urban cities of Gabon.
Bouyou-Akotet MK; Mawili-Mboumba DP; Kendjo E; Moutandou Chiesa S; Tshibola Mbuyi ML; Tsoumbou-Bakana G; Zong J; Ambounda N; Kombila M
Trans R Soc Trop Med Hyg; 2016 Jun; 110(6):333-42. PubMed ID: 27268713
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of intermittent preventive treatment and intermittent screening and treatment versus single screening and treatment with dihydroartemisinin-piperaquine for the control of malaria in pregnancy in Indonesia: a cluster-randomised, open-label, superiority trial.
Ahmed R; Poespoprodjo JR; Syafruddin D; Khairallah C; Pace C; Lukito T; Maratina SS; Asih PBS; Santana-Morales MA; Adams ER; Unwin VT; Williams CT; Chen T; Smedley J; Wang D; Faragher B; Price RN; Ter Kuile FO
Lancet Infect Dis; 2019 Sep; 19(9):973-987. PubMed ID: 31353217
[TBL] [Abstract][Full Text] [Related]
33. Variable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children.
Sundell K; Jagannathan P; Huang L; Bigira V; Kapisi J; Kakuru MM; Savic R; Kamya MR; Dorsey G; Aweeka F
Malar J; 2015 Sep; 14():368. PubMed ID: 26403465
[TBL] [Abstract][Full Text] [Related]
34. Identifying an optimal dihydroartemisinin-piperaquine dosing regimen for malaria prevention in young Ugandan children.
Wallender E; Ali AM; Hughes E; Kakuru A; Jagannathan P; Muhindo MK; Opira B; Whalen M; Huang L; Duvalsaint M; Legac J; Kamya MR; Dorsey G; Aweeka F; Rosenthal PJ; Savic RM
Nat Commun; 2021 Nov; 12(1):6714. PubMed ID: 34795281
[TBL] [Abstract][Full Text] [Related]
35. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria.
Lwin KM; Phyo AP; Tarning J; Hanpithakpong W; Ashley EA; Lee SJ; Cheah P; Singhasivanon P; White NJ; Lindegårdh N; Nosten F
Antimicrob Agents Chemother; 2012 Mar; 56(3):1571-7. PubMed ID: 22252804
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Ugandan children: a systematic review and meta-analysis of randomized control trials.
Assefa DG; Zeleke ED; Bekele D; Tesfahunei HA; Getachew E; Joseph M; Manyazewal T
Malar J; 2021 Apr; 20(1):174. PubMed ID: 33794897
[TBL] [Abstract][Full Text] [Related]
37. Comparative Efficacy of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Ugandan Children.
Yeka A; Wallender E; Mulebeke R; Kibuuka A; Kigozi R; Bosco A; Kyambadde P; Opigo J; Kalyesubula S; Senzoga J; Vinden J; Conrad M; Rosenthal PJ
J Infect Dis; 2019 Mar; 219(7):1112-1120. PubMed ID: 30418593
[TBL] [Abstract][Full Text] [Related]
38. Prevention and control of malaria in pregnancy - new threats, new opportunities?
Rogerson SJ; Unger HW
Expert Rev Anti Infect Ther; 2017 Apr; 15(4):361-375. PubMed ID: 27973923
[TBL] [Abstract][Full Text] [Related]
39. Randomized trial of 2-dose versus monthly sulfadoxine-pyrimethamine intermittent preventive treatment for malaria in HIV-positive and HIV-negative pregnant women in Malawi.
Filler SJ; Kazembe P; Thigpen M; Macheso A; Parise ME; Newman RD; Steketee RW; Hamel M
J Infect Dis; 2006 Aug; 194(3):286-93. PubMed ID: 16826475
[TBL] [Abstract][Full Text] [Related]
40. Intermittent screening and treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy: implementation feasibility in a routine healthcare system setting in western Kenya.
Hill J; Ouma P; Oluoch S; Bruce J; Kariuki S; Desai M; Webster J
Malar J; 2020 Nov; 19(1):433. PubMed ID: 33238999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
